VP04.09: COVID‐19 and adnexal tumours: did the first year of the pandemic modify the care or the profile of our patients?

Our objective is to analyse the impact of pandemic on diagnosis and treatment adnexal tumours support available women living with disease. We retrospectively analysed pre post COVID-19 medical records those patients submitted for tumour suspicious malignancy or benign prior surgery. Diagnosis algorithms did not change compared previous ones. The explorations were performed by same IOTA certified sonographer. classified as low high risk ADNEX low-risk non-surgical management cited every 3 months. considered from January/17 December/19, January December/20. 608 included, 453 155 COVID-19. During era, 67,5% (306) 32,5% (147) risk. 299 required surgery during this period: 66,8% (200) benign, 8,6% (26) stage I ovarian cancer, 14% (42) II-IV, 2,6% (8) metastasis 7,3% (22) borderline. 69,6% (108) 30,4% (47) 103 57,2% (59) 10,6% (11) 21,3% 0,97% (1) 9,7% (10) In our population, we haven't observed a decrease in total number referred cancer but an increase emergency units. objectified increasing I, II-IV borderline period before. consider these findings be related fears themselves about accessing assistance, since attending oncological pathology remained essential activity hospital. allows us discriminate between risks tumour, which could have management.